Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851785 | 1.00 | HTR2A (0.40) | HTR2AHTR2CNOTUMKMT2ADAO | |
| Hydroxyamine SCHEMBL9656520 | 0.94 | HTR2A (0.37) | HTR2AHTR2CNOTUMKMT2ADAO | |
| SCHEMBL3211491 | 0.87 | HTR2A (0.37) | HTR2AHTR2CNOTUMKMT2A | |
| SCHEMBL5253279 | 0.78 | DAO (0.40) | DAOMCL1SIGMAR1ALDH1A1TSHR | |
| SCHEMBL3203395 | 0.77 | HTR2A (0.35) | HTR2AHTR2CNOTUM | |
| SCHEMBL4860771 | 0.76 | HTR2A (0.30) | HTR2AHTR2C | |
| SCHEMBL11009537 | 0.74 | NOTUM (0.38) | HTR2AHTR2CNOTUMKMT2ADAO | |
| SCHEMBL641455 | 0.72 | KMT2A (0.37) | HTR2AHTR2CKMT2AALDH1A1TSHR | |
| SCHEMBL18229897 | 0.71 | HTR2A (0.49) | HTR2AHTR2CNOTUMSIGMAR1 | |
| SCHEMBL1383923 | 0.68 | HTR2A (0.43) | HTR2AHTR2CNOTUMKMT2ADAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232580-A | A kind of synthetic method of 1H- pyrrolo- [1,2-a] indoles -2 (3-H) -one | 南阳师范学院 | 2019-01-18 | — | — | CN | claimed |
| US-20130189373-A1 | Method of Treating Cancer Using Combination of a Bifunctional Alkylating Agent and DNA Repair Inhibitors | Academai Sinica (TW) | 2013-07-25 | — | — | US | claimed |
| WO-2011056663-A1 | METHOD OF TREATING CANCER USING COMBINATION OF A BIFUNCTIONAL ALKYLATING AGENT AND DNA REPAIR INHIBITORS | ACADEMIA SINICA (TW) | 2011-05-12 | — | — | WO | claimed |
| EP-1652554-B1 | Composition comprising at least one carboycanine, process of treating keratinic fibres, kit and use of said composition | OREAL (FR) | 2010-01-13 | — | — | EP | claimed |
| US-7425221-B2 | Composition comprising at least one substituted derivative of carbocyanine, method for treating keratin fibers using it, device and use | L'OREAL S.A. (FR) | 2008-09-16 | — | — | US | claimed |
| US-20060195990-A1 | Composition comprising at least one substituted derivative of carbocyanine, method for treating keratin fibers using it, device and use | L'OREAL S.A. (FR) | 2006-09-07 | — | — | US | claimed |
| EP-1652554-A1 | Composition comprising at least one carboycanine, process of treating keratinic fibres, kit and use of said composition | L'OREAL (FR) | 2006-05-03 | — | — | EP | claimed |
| WO-2006030127-A1 | COMPOSITION COMPRISING AT LEAST ONE SUBSTITUTED CARBOCYANINE DERIVATIVE, KERATIN FIBRE TREATMENT METHOD USING SAME, ASSOCIATED DEVICE AND USE THEREOF | L'OREAL (FR) | 2006-03-23 | — | — | WO | claimed |
| EP-0718299-B1 | Tricyclic oxime ethers process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2000-04-05 | — | — | EP | claimed |
| US-5627203-A | INHIBITORS OF SEROTONIN REUPTAKE, HIGH AFFINITY FOR 5HT RECEPTORS, ANXIOLYTIC, ANTIDEPRESSANT | ADIR ET COMPAGNIE (FR) | 1997-05-06 | — | — | US | claimed |
| CN-1131155-A | Tricyclic oxime ethers, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1996-09-18 | — | — | CN | claimed |
| EP-0718299-A1 | Tricyclic oxime ethers process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-06-26 | — | — | EP | claimed |
| US-4134894-A | Pyrrolo[1,2-a]indole compounds | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | claimed |
| WO-2025077825-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS | FAUNA BIO INCORPORATED (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-105503882-B | The method for preparing S1P1 receptor modulators and its crystal form | 艾尼纳制药公司 | 2019-07-05 | — | — | CN | disclosed |
| CN-105744957-B | The method for preparing the pharmaceutical composition containing mitomycin C of freeze-drying | 默德克学会特殊临床公司 | 2019-07-02 | — | — | CN | disclosed |
| US-4778812-A | ANTIHYPOXIC AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0246094-A2 | Mitomycin derivatives | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1987-11-19 | — | — | EP | disclosed |
| US-4134894-A | Pyrrolo[1,2-a]indole compounds | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
| US-4134894-A | Pyrrolo[1,2-a]indole compounds | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189373-A1 | Method of Treating Cancer Using Combination of a Bifunctional Alkylating Agent and DNA Repair Inhibitors | TOP2A, UNG, MRE11 | HTR2A 4168/4885HTR2C 4639/4885NOTUM 3498/4885 |
| US-20060195990-A1 | Composition comprising at least one substituted derivative of carbocyanine, method for treating keratin fibers using it, device and use | KRT18, KLK5, IK | HTR2A 4296/4885HTR2C 3609/4885NOTUM 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.